- Tags: AMD
Legal
Regeneron settles with Sandoz over Eylea biosimilar patent infringement lawsuit
Agreement enables FDA-approved Enzeevu (aflibercept-abzv) to launch in Q4 2026, or potentially earlier.
Research
What factors impact visual acuity in intermediate AMD?
Study identifies three key features that impact visual acuity in patients with intermediate AMD.
Business
Alcon officially purchases LumiThera
Acquisition of the Valeda Light Delivery System includes plans to expand commercial market availability in 2026.
Pipeline
Outlook Therapeutics receives second FDA CRL over wet AMD BLA
Agency rejects submission of bevacizumab-vikg for a second time, citing a single issue with the application: a lack of effectiveness data.
Research
Are blue light-filtering IOLs beneficial for AMD?
Blue light-filtering IOLs demonstrate no protective effect on the risk of developing exudative AMD.
Pipeline
FDA extends review period for EYLEA HD expanded labeling
Delay follows a recent site inspection; proposed expansion includes a new indication, updated dosings for current indications, and a pre-filled syringe version.
Research
Study links gout patients with increased AMD risk and progression
Activation of similar inflammatory pathways may explain the observed association.
Research
Genentech reports 5-year results on SUSVIMO for wet AMD
Presented at ASRS, new data reinforce the ranibizumab injection’s ability to provide an immediate and predictable durability as an alternative to regular eye injections.
Pipeline
4DMT releases 60-week phase 2 analysis on wet AMD gene therapy
Reported at ASRS, data supports sustained vision gains and a 78% reduction in supplemental injections for 4D-150’s highest dose as company preps for phase 3 trial.
Products
Altris AI launches new app for direct OCT syncing
Altris Sync software syncs directly to OCT devices from eight leading manufacturers, enabling automated OCT file uploading and eliminating the need for manual operation.
Business
Topcon invests in OKKO Health's home vision monitoring platform
The OKKO Health app is available on patients’ digital devices to enable ongoing self-monitoring of macular degeneration.
Pipeline
FDA grants Sanofi Fast Track designation for GA gene therapy
Status gives expedited pathway toward regulatory approval for SAR446597, designed as a one-time injection that blocks two of the three complement system pathways.
Business
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio
Acquisition includes two major anti-VEGF therapies for retinal diseases: OPUVIZ and BYOOVIZ, generic equivalents to EYLEA and Lucentis, respectively.
Pipeline
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant
Also under clinical development for Stargardt disease, the once-daily tablet is under evaluation for its efficacy in slowing atrophic lesion growth.
Research
Pivotal study validates SCANLY Home OCT device for nAMD management
New research further supports the clinical performance of Notal Vision's FDA-cleared, AI-based OCT monitoring system for at-home use.
Business
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
Company reports streamlined planning to advance phase 3 clinical trials of 4D-150, under evaluation to deliver a single, low-dose, and sustained multi-year intravitreal injection.Business
Alcon to purchase LumiThera
Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Research
AOA report analyzes ocular risks of GLP-1RAs
Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Research
GLP-1 drug users twice as likely to develop nAMD
New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.
Research